Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
7 search results for:

WCLC 2022 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 16-08-2022 | WCLC 2022 | Conference coverage | Article

    Entrectinib shows potential as first-line treatment for ROS1 fusion-positive advanced NSCLC

    The fourth update from the phase 1/2 STARTRK-1, STARTRK-2, and ALKA-372-001 studies was presented at the IASLC World Conference on Lung Cancer 2022 in Vienna, Austria, by Yun Fan (Zhejiang Cancer Hospital, Hangzhou, China).

    Author:
    Lynda Williams
    Published in:
    IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August
  2. 12-08-2022 | WCLC 2022 | Conference coverage | Article
    News in brief

    Recent thoracic cancer systemic therapy does not increase risk for death after COVID-19

    IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August

    Author:
    Lynda Williams
    Published in:
    IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August
  3. 11-08-2022 | WCLC 2022 | Conference coverage | Article

    Sugemalimab continues to show stage III unresectable NSCLC benefits after chemoradiation

    Final analysis of progression-free survival in the GEMSTONE-301 trial shows a significant improvement with use of sugemalimab versus placebo after chemoradiotherapy for stage III unresectable non-small-cell lung cancer, report Chinese researchers at the IASLC World Conference on Lung Cancer 2022 in Vienna, Austria.

    Author:
    Lynda Williams
    Published in:
    IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August
  4. 11-08-2022 | WCLC 2022 | Conference coverage | Article

    KEYNOTE-604 update bolsters first-line pembrolizumab–chemo for extensive-stage SCLC

    And he added that there are a number of ongoing trials within this space. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August

    Author:
    Shreeya Nanda
    Published in:
    IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August
  5. 09-08-2022 | WCLC 2022 | Conference coverage | Article

    NADIM II: Adding nivolumab to neoadjuvant chemo improves stage III NSCLC survival

    The discussant concluded that “the time is probably ripe for a clinical trial comparing a surgical to a nonsurgical approach, with good integration of biomarkers for patient selection.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August

    Author:
    Shreeya Nanda
    Published in:
    IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August
  6. 10-08-2022 | WCLC 2022 | Conference coverage | Article

    ​​​​​​​Sub-lobar resection ‘new standard of care’ for small-sized NSCLC

    Saji concluded that they hope to conduct a meta-analysis to further dissect the results by subgroups, including type of sub-lobar resection, nodal factors, and histology among others. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August

    Author:
    Shreeya Nanda
    Published in:
    IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August
  7. 09-08-2022 | WCLC 2022 | Conference coverage | Article

    ​​​​​​​IMpower010 shows OS trend favoring adjuvant atezolizumab in certain NSCLC patients

    Finally, Besse said that he hopes that “in academia we will be able to do de-escalation trials with these very expensive drugs.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August

    Author:
    Shreeya Nanda
    Published in:
    IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.